Please login to the form below

Not currently logged in

Challenge to perception of US R&D

A paper has challenged the assumption that the US is way ahead of Europe in pharmaceutical research productivity

A paper published in the journal Health Affairs has challenged the assumption that the US is way ahead of Europe in pharmaceutical research productivity.

Donald Light, Lorry Lokey visiting professor at Stanford University, California and a professor of social medicine in the Department of Psychiatry at the University of Medicine and Dentistry of New Jersey, re-examined research previously used to demonstrate US firms' superiority in innovation.  

Light believes that Europe would be seen in a stronger position if key data, such as new first-in-class and orphan drugs launched here but not in the US, were included in calculations. He also points out that new chemical entities (NCEs) are assigned to the country in which the launching company is headquartered – for 12 of the 20 biggest companies this means the US. If they were attributed to the country in which the actual research was carried out, then Europe's standing would be higher.

Evidence of strong research in Europe, where drugs prices tend to be lower than the US, counters the argument that high prices for patented drug are necessary to fund R&D. 

Light also expresses the view that, too often, performance against placebo is used to justify bringing NCEs to market. He calls for incentives for companies to develop drugs that demonstrate real advantage over treatments already on the market.

1st September 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...